GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Homology Medicines (Homology Medicines) Cash, Cash Equivalents, Marketable Securities : $82.65 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Cash, Cash Equivalents, Marketable Securities?

Homology Medicines's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($127.07 Mil) to Sep. 2023 ($103.30 Mil) but then stayed the same from Sep. 2023 ($103.30 Mil) to Dec. 2023 ($82.65 Mil).

Homology Medicines's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($155.87 Mil) to Dec. 2022 ($175.03 Mil) but then declined from Dec. 2022 ($175.03 Mil) to Dec. 2023 ($82.65 Mil).


Homology Medicines Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Homology Medicines's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Cash, Cash Equivalents, Marketable Securities Chart

Homology Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 262.39 217.43 155.87 175.03 82.65

Homology Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.03 150.03 127.07 103.30 82.65

Homology Medicines Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Homology Medicines  (NAS:FIXX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Homology Medicines Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Homology Medicines (Homology Medicines) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Executives
Paul Alloway officer: See Remarks C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour officer: Chief Scientific Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum officer: Chief Commercial Officer C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith officer: CFO, Treasurer & Secretary C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos director, officer: President & CEO C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly officer: See Remarks C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn director, 10 percent owner, other: *Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty officer: Chief Operating Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109

Homology Medicines (Homology Medicines) Headlines

From GuruFocus